J&J and Lilly buy biotech pipelines, with prices that depend on results
Johnson & Johnson (J&J), the US healthcare group, agreed on 16 November to buy the eye-disease biotech Ollin Biosciences for up to $3.3bn, which the FT describes as the latest in a glut of biotech deals. The same day, Eli Lilly, the Indianapolis-based US drugmaker, agreed to buy Calytrix Bio, a privately held biotech, for up to $1.5bn, adding to the $32bn Lilly has spent on acquisitions in 2026 to build its cancer and immunology businesses (Bloomberg). Bloomberg Intelligence’s Sam Fazeli, its director of research for global industries, says AI is playing a role in new developments in the sector.
Nasdaq 100 drops more than 2% after Nvidia news
The Nasdaq 100, the index of the 100 largest non-financial companies listed on the Nasdaq exchange and a gauge of how investors value US technology firms, fell more than 2% in afternoon trading on 16 November amid what the FT calls “Nvidia fallout”. Anthropic’s planned IPO pricing on 18 November, which we predicted, is two days away, so market conditions are worth watching.
Bank of Canada’s Macklem to leave in June
Tiff Macklem, governor of the Bank of Canada, will leave in June, which starts the search for a successor (WSJ). His successor takes over while Canada’s economy tries to reduce its dependence on trade with the US to drive growth (WSJ).
JD Sports says brands are absorbing US tariffs
JD Sports chief executive Regis Schultz called the US “the most resilient customer”, according to Bloomberg. He said JD’s stores have not felt much tariff impact because the brands they stock are taking most of the hit.
Stay tuned for the next Gist—your edge in a shifting world. The Gist remains independent and reader-supported. If you value news free from corporate or state interests, consider supporting our mission with a donation.